Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37.

J Le, Q Dam, M Schweizer, W Thienphrapa, V Nizet, G Sakoulas
Author Information
  1. J Le: Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, MC 0714, La Jolla, CA, 92093-0714, USA. jenle@ucsd.edu.
  2. Q Dam: University of California San Diego School of Medicine, La Jolla, CA, USA.
  3. M Schweizer: Iowa City VA Health Care System, Iowa City, IA, USA.
  4. W Thienphrapa: University of California San Diego School of Medicine, La Jolla, CA, USA.
  5. V Nizet: Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, MC 0714, La Jolla, CA, 92093-0714, USA.
  6. G Sakoulas: University of California San Diego School of Medicine, La Jolla, CA, USA.

Abstract

Recent studies have demonstrated that anti-staphylococcal beta-lactam antibiotics, like nafcillin, render methicillin-resistant Staphylococcus aureus (MRSA) more susceptible to killing by innate host defense peptides (HDPs), such as cathelicidin LL-37. We compared the effects of growth in 1/4 minimum inhibitory concentration (MIC) of nafcillin or vancomycin on the LL-37 killing of 92 methicillin-susceptible S. aureus (MSSA) isolates. For three randomly selected strains among these, we examined the effects of nafcillin, vancomycin, daptomycin, or linezolid on LL-37 killing and autolysis. Growth in the presence of subinhibitory nafcillin significantly enhanced LL-37 killing of MSSA compared to vancomycin and antibiotic-free controls. Nafcillin also reduced MSSA production of the golden staphylococcal pigment staphyloxanthin in 39 % of pigmented strains vs. 14 % for vancomycin. Among the antibiotics tested, only nafcillin resulted in significantly increased MSSA autolysis. These studies point to additional mechanisms of anti-staphylococcal activity of nafcillin beyond direct bactericidal activity, properties that vancomycin and other antibiotic classes do not exhibit. The ability of nafcillin to enhance sensitivity to innate HDPs may contribute to its superior effectiveness against MSSA, as suggested by studies comparing clinical outcomes to vancomycin treatment.

References

  1. J Mol Med (Berl). 2014 Feb;92(2):139-49 [PMID: 24297496]
  2. Trends Microbiol. 2009 Sep;17(9):406-13 [PMID: 19726196]
  3. Antimicrob Agents Chemother. 2008 Jan;52(1):192-7 [PMID: 17984229]
  4. Curr Protein Pept Sci. 2013 Sep;14(6):504-14 [PMID: 23968350]
  5. Clin Infect Dis. 2011 Jul 15;53(2):158-63 [PMID: 21690622]
  6. Antimicrob Agents Chemother. 2005 Jul;49(7):2687-92 [PMID: 15980337]
  7. Infect Control Hosp Epidemiol. 2012 Feb;33(2):160-6 [PMID: 22227985]
  8. FASEB J. 2007 Apr;21(4):1107-16 [PMID: 17215486]
  9. Antimicrob Agents Chemother. 2012 Oct;56(10):5164-70 [PMID: 22825122]
  10. BMC Infect Dis. 2011 Oct 19;11:279 [PMID: 22011388]
  11. N Engl J Med. 2006 Aug 17;355(7):653-65 [PMID: 16914701]
  12. J Infect Dis. 2011 Aug 1;204(3):340-7 [PMID: 21742831]
  13. Am J Physiol Cell Physiol. 2011 Jan;300(1):C105-12 [PMID: 20943960]
  14. Antimicrob Agents Chemother. 2011 Nov;55(11):5122-6 [PMID: 21825299]
  15. J Antimicrob Chemother. 2008 Jun;61(6):1266-9 [PMID: 18367458]
  16. Clin Infect Dis. 2007 Jan 15;44(2):190-6 [PMID: 17173215]
  17. Curr Opin Hematol. 2009 Jan;16(1):41-7 [PMID: 19068548]
  18. Clin Infect Dis. 2003 Jan 1;36(1):53-9 [PMID: 12491202]
  19. Cell Immunol. 2012 Nov;280(1):22-35 [PMID: 23246832]
  20. Antimicrob Agents Chemother. 2012 Apr;56(4):1854-61 [PMID: 22252821]
  21. Antimicrob Agents Chemother. 2014;58(3):1494-500 [PMID: 24366742]
  22. Clin Infect Dis. 2009 Feb 15;48(4):418-24 [PMID: 19133797]
  23. Antimicrob Agents Chemother. 2012 Feb;56(2):838-44 [PMID: 22123698]
  24. Infect Immun. 2003 Jul;71(7):3730-9 [PMID: 12819054]
  25. Antimicrob Agents Chemother. 2008 Mar;52(3):831-6 [PMID: 17999971]
  26. PLoS One. 2010 Jul 02;5(7):e11432 [PMID: 20625395]
  27. Clin Infect Dis. 2013 Dec;57(12):1760-5 [PMID: 23985343]

Grants

  1. R37 AI052453/NIAID NIH HHS
  2. P50 HD090259/NICHD NIH HHS
  3. K23 AI089978/NIAID NIH HHS
  4. U54 AI057153/NIAID NIH HHS
  5. U54 HD071600/NICHD NIH HHS

MeSH Term

Anti-Bacterial Agents
Antimicrobial Cationic Peptides
Bacteremia
Bacteriolysis
Drug Interactions
Humans
Microbial Sensitivity Tests
Microbial Viability
Nafcillin
Staphylococcal Infections
Staphylococcus aureus
Vancomycin
Cathelicidins

Chemicals

Anti-Bacterial Agents
Antimicrobial Cationic Peptides
Nafcillin
Vancomycin
Cathelicidins

Word Cloud

Created with Highcharts 10.0.0nafcillinvancomycinkillingLL-37MSSAstudiesaureusanti-staphylococcalantibioticsStaphylococcusinnateHDPscathelicidincomparedeffectsmethicillin-susceptiblestrainsautolysissignificantlyactivityRecentdemonstratedbeta-lactamlikerendermethicillin-resistantMRSAsusceptiblehostdefensepeptidesgrowth1/4minimuminhibitoryconcentrationMIC92SisolatesthreerandomlyselectedamongexamineddaptomycinlinezolidGrowthpresencesubinhibitoryenhancedantibiotic-freecontrolsNafcillinalsoreducedproductiongoldenstaphylococcalpigmentstaphyloxanthin39 %pigmentedvs14 %AmongtestedresultedincreasedpointadditionalmechanismsbeyonddirectbactericidalpropertiesantibioticclassesexhibitabilityenhancesensitivitymaycontributesuperioreffectivenesssuggestedcomparingclinicaloutcomestreatmentEffectsversusenhancingcausingbacteremiahuman

Similar Articles

Cited By